Lv1
60 积分 2021-07-09 加入
[Consensus recommendations on utilizing glucagon-like peptide-1(GLP-1) receptor agonists in the treatment of type 2 diabetes mellitus]
3个月前
已完结
Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project)
3个月前
已完结
Management of obesity
3个月前
已完结
Comparison of the mean of the first two blood pressure readings with the overall mean of three readings on a single occasion
3个月前
已完结
Effects of oral antidiabetic agents on the renin–angiotensin–aldosterone system
4个月前
已完结
GLP-1R agonists: recent advances, current gaps, and future challenges
4个月前
已完结
Unraveling the safety profile of GLP-1 receptor agonists: Mechanistic insights with a focus on semaglutide
4个月前
已完结
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
5个月前
已完结
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
5个月前
已完结
Polycystic ovary syndrome as a metabolic disease
7个月前
已完结
皖公网安备34019202002308
